STOCK TITAN
  1. Home
  2. Sec-filings
  3. UNCY
  4. [Form 4/A] Unicycive Therapeutics, Inc. Amended Insider Trading Activity

Director Laumas receives new RSU awards at Unicycive (NASDAQ: UNCY)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.

Unicycive Therapeutics director Sandeep Laumas received two equity compensation grants in the form of restricted stock units (RSUs). The Form 4/A reports awards covering 42,100 and 84,200 RSUs, each payable solely in Unicycive common stock.

Footnotes explain that one RSU award provides 11,694 shares vesting upon grant and 2,339 shares vesting monthly over 31 months beginning June 1, 2026, subject to his continued service. A second annual RSU award provides 17,542 shares vesting upon grant and 3,508 shares vesting monthly over 7 months beginning the same date, also contingent on continued service. These are compensation-related grants at a stated price of $0.00 per unit, not open‑market share purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Laumas Sandeep
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Units 84,200 $0.00 $0.00
Grant/Award Restricted Stock Units 42,100 $0.00 $0.00
Holdings After Transaction: Restricted Stock Units — 126,300 shares (Direct)
Footnotes (2)
  1. F1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
  2. F2. Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
RSUs granted 42,100 RSUs Restricted Stock Units awarded to director on May 14, 2026
Additional RSUs granted 84,200 RSUs Second RSU award to director on May 14, 2026
Immediate vesting portion 11,694 shares Shares vesting upon grant under RSU Award per footnote
Monthly vesting installment 2,339 shares Monthly vesting over 31 months beginning June 1, 2026
Annual award immediate vesting 17,542 shares Shares vesting upon grant under Annual RSU Award
Annual award monthly vesting 3,508 shares Monthly vesting over 7 months beginning June 1, 2026
Underlying common stock 126,300 shares Total underlying shares for both RSU grants combined
Restricted Stock Units financial
"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSU Award financial
"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"
Annual RSU Award financial
"Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock"
vesting financial
"11,694 shares vest upon grant and 2,339 vest monthly over 31 months"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
underlying security financial
"underlying_security_title": "Common Stock", "underlying_security_shares": "42100.0000""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Unicycive (UNCY) disclose in this Form 4/A for Sandeep Laumas?
Unicycive disclosed that director Sandeep Laumas received two grants of restricted stock units as equity compensation. The awards cover 42,100 and 84,200 RSUs, each payable solely in Unicycive common stock, with vesting tied to his continued service with the company.

How many restricted stock units did Unicycive (UNCY) grant to director Sandeep Laumas?
The filing reports RSU grants of 42,100 and 84,200 units to director Sandeep Laumas. Each RSU represents a right to receive one share of Unicycive common stock, subject to specific vesting schedules and his continued service with the company over defined periods.

What are the vesting terms of the RSU awards reported for Unicycive (UNCY)?
One RSU award vests 11,694 shares upon grant and 2,339 shares monthly over 31 months from June 1, 2026. A second annual RSU award vests 17,542 shares upon grant and 3,508 shares monthly over 7 months from that same June 1, 2026 start date.

Are the Unicycive (UNCY) RSU grants to Sandeep Laumas open-market share purchases?
No, the RSU grants are compensation awards, not open-market purchases. They are reported with a transaction price of $0.00 per unit and are payable solely in Unicycive common stock, vesting over time based on continued service with the issuer.

When does vesting begin for the Unicycive (UNCY) RSU awards to director Laumas?
Both RSU footnotes state that monthly vesting begins on June 1, 2026. Portions of each award also vest immediately upon grant, with the remaining shares vesting in equal monthly installments over 31 months and 7 months, respectively, conditioned on continued service.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Laumas Sandeep
(Last)(First)(Middle)
C/O UNICYCIVE THERAPEUTICS, INC.
1975 W. EL CAMINO REAL, SUITE 204
(Street)
MOUNTAIN VIEW CALIFORNIA 94040
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Unicycive Therapeutics, Inc. [ UNCY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
05/18/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$005/14/2026A84,200 (1) (1)Common Stock84,200$084,200D
Restricted Stock Units$005/14/2026A42,100 (2) (2)Common Stock42,100$0126,300D
Explanation of Responses:
1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
2. Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
/s/ Sandeep Laumas06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR